Group 1 - The National Healthcare Security Administration (NHSA) has introduced a "green channel" for medical insurance coding for innovative medical products such as brain-computer interfaces (BCIs) [1] - The NHSA will expedite the coding process for products that have obtained medical device registration certificates and will also support products that have not yet received certification by allowing submission of technical requirements and clinical evaluation materials [1] - The aim of this initiative is to optimize the classification system for medical consumables under insurance, ensuring it adapts to industry developments and promotes the rapid clinical use of innovative medical products [1] Group 2 - There has been a significant increase in policy support for the brain-computer interface market this year, with the establishment of a comprehensive terminology system for BCIs set to be implemented in January 2026 [2] - The NHSA has introduced independent billing items for BCI technologies, laying the groundwork for future commercialization and clinical application [2] - By 2027, key breakthroughs in BCI technology are expected, with the establishment of advanced technical, industrial, and standard systems, and the application of BCI products across various sectors [2] Group 3 - Major companies are entering the commercialization phase, with the approval of China's first invasive BCI medical device by Nanjing Shanhai Medical Technology Co., Ltd. [3] - Companies like Sainuo Medical and Xiangyu Medical are leveraging their expertise to develop minimally invasive BCI solutions and rehabilitation devices for stroke patients [3] - Sanbo Neuroscience has successfully implanted invasive BCI devices in patients with ALS, enabling them to control robotic arms through thought [3]